GEN 1501
Alternative Names: GEN-1501; Lantus biosimilarLatest Information Update: 28 Dec 2020
At a glance
- Originator GeneSys Biologics
- Class Antihypercalcaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 30 Nov 2020 Preclinical trials in Diabetes mellitus in India (SC) prior to October 2020
- 30 Nov 2020 GeneSys Biologics plans a phase I bioequivalence study in volunteers in India (SC, Injection) in October 2020 (CTRI/2020/09/027956)